Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

 

  • Neurotransmitter based
  • Neuroprotective
  • Anti-inflammatory
  • Cognitive enhancers

Related Conference of Drug Development in Dementia

October 18-20, 2018

International Conference & Expo on Clinical Psychology


Hyatt Place Amsterdam Airport, Amsterdam, Netherlands
November 12-13, 2018

30th International Conference on Mental and Behavioral Health

Melbourne, Australia
November 19-20, 2018 | Paris, France |

Annual Congress on Psychiatric & Mental Health Nursing

Holiday Inn Paris – Marne La Vallée
November 26-27, 2018

World Summit on Psychiatry, Mental Health Nursing and Healthcare

Los Angeles, California, USA
January 23-24, 2019

Global Conference on Forensic Psychology & Criminology

Paris, France
February 27-28, 2019

7th World Congress on Depression and Anxiety

Seoul, South Korea

March 14 & 15, 2019

European Autism Congress

| Zagreb, Croatia
March, 14-15, 2019 |

European Psychiatrists Meeting

Zagreb, Croatia.
March 29-30, 2019

31st American Psychiatry and Psychology Congress

Orlando, Florida, USA
June 13th - 15th 2019

2nd Annual Congress on Mental Health

Amsterdam, Netherlands
June 24-25, 2019

31stWorld Psychiatrists and Psychologists Meet

Ho Chi Minh City, Vietnam

Drug Development in Dementia Conference Speakers

Recommended Sessions

Related Journals

Are you interested in